\(
\def\WIPO{World Intellectual Property Organisation}
\)
Lucence: Lighting up the Future of Cancer Care
2023
Formats
| Format | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DataCite | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Cite
Details
Title
Lucence: Lighting up the Future of Cancer Care
Item Type
Journal article
Description
1 article.
Summary
One in three people will get cancer in their lifetime. This stark statistic makes early detection of cancer - when the disease is more treatable and curable - a “must.” A hyper-sensitive blood test developed by Lucence, a precision oncology company based in Singapore and the USA, promises to make early detection a reality. Through its ground-breaking technology, Lucence is working to improve cancer care and cure rates through a simple blood test. Its ultra-sensitive liquid biopsy tests make it possible to profile cancer accurately, rapidly and affordably with a single blood draw, allowing physicians to make better treatment decisions and improve health outcomes. Dr. Min-Han Tan, Founder and CEO of Lucence, talks to WIPO Magazine about his company’s commitment to saving the lives of cancer patients around the world through earlier detection of the disease.
Series
Linked Resources
Translations
Published
Geneva, Switzerland : World Intellectual Property Organization, 2023.
Language
English
Record Appears in